KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Leases: 2019-2025

Historic Operating Leases for Jazz Pharmaceuticals (JAZZ) over the last 7 years, with Sep 2025 value amounting to $53.4 million.

  • Jazz Pharmaceuticals' Operating Leases fell 24.87% to $53.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.4 million, marking a year-over-year decrease of 24.87%. This contributed to the annual value of $38.9 million for FY2024, which is 34.25% down from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Operating Leases is $53.4 million, which was down 3.05% from $55.1 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Operating Leases peaked at $177.1 million during Q2 2021, and registered a low of $38.8 million during Q1 2025.
  • Over the past 3 years, Jazz Pharmaceuticals' median Operating Leases value was $59.2 million (recorded in 2023), while the average stood at $58.2 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Operating Leases crashed by 56.03% in 2022 and then increased by 14.90% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Operating Leases (Quarterly) stood at $87.2 million in 2021, then dropped by 17.62% to $71.8 million in 2022, then fell by 17.56% to $59.2 million in 2023, then slumped by 34.25% to $38.9 million in 2024, then fell by 24.87% to $53.4 million in 2025.
  • Its Operating Leases was $53.4 million in Q3 2025, compared to $55.1 million in Q2 2025 and $38.8 million in Q1 2025.